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Summary
PGC-1b is a transcriptional coactivator that potently stimulates mitochondrial biogenesis and respiration of cells. Here, we
have generated mice lacking exons 3 to 4 of the Pgc-1b gene (Pgc-1bE3,42/E3,42 mice). These mice express a mutant protein
that has reduced coactivation activity on a subset of transcription factors, including ERRa, a major target of PGC-1b in the
induction of mitochondrial gene expression. The mutant mice have reduced expression of OXPHOS genes and mitochondrial
dysfunction in liver and skeletal muscle as well as elevated liver triglycerides. Euglycemic-hyperinsulinemic clamp and
insulin signaling studies show that PGC-1b mutant mice have normal skeletal muscle response to insulin but have hepatic
insulin resistance. These results demonstrate that PGC-1b is required for normal expression of OXPHOS genes and mito-
chondrial function in liver and skeletal muscle. Importantly, these abnormalities do not cause insulin resistance in skeletal
muscle but cause substantially reduced insulin action in the liver.Introduction
Type 2 diabetes mellitus (DM2) is one of the most common
metabolic disorders worldwide and is a major cause of blind-
ness, renal failure, limb gangrene, and cardiovascular disease
(Kahn, 1998; Zimmet et al., 2001). The primary cause of DM2 re-
mains to be understood. It is clear, however, that insulin resis-
tance is an early feature of DM2 (Shulman, 2000). Insulin resis-
tance is consistently found in DM2 subjects and may be
detected decades before the onset of DM2 (Lillioja et al.,
1988, 1993; Warram et al., 1990). Moreover, in subjects with
a family history of DM2, insulin resistance is the best predictor
for the development of DM2 (Lillioja et al., 1993; Warram et al.,
1990).
Insulin resistance is the failure of target tissues to respond
properly to insulin. Liver and skeletal muscle are among the
major sites of insulin action. Insulin reduces liver glucose pro-
duction and stimulates glucose uptake into skeletal muscle.
The development of insulin resistance in these tissues accounts
for major alterations in glucose metabolism seen in DM2 sub-
jects. Various factors have been implicated as being causally re-
lated to insulin resistance (Lazar, 2005; Lowell and Shulman,
2005); nevertheless, the underlying cellular mechanisms of insu-
lin resistance in these tissues remain to be fully elucidated.CELL METABOLISM 4, 453–464, DECEMBER 2006 ª2006 ELSEVIER INRecently, two independent gene expression profile studies
identified a set of genes consistently downregulated in skeletal
muscle of DM2 patients, oxidative phosphorylation (OXPHOS)
genes (Mootha et al., 2003; Patti et al., 2003). Among them
were several genes encoding subunits of complexes I to V of the
respiratory chain, which were modestly (20%) but coordinately
reduced. Moreover, the same set of genes were also found to
be reduced in prediabetics with a family history of DM2 (Patti
et al., 2003), demonstrating that reduction of OXPHOS gene
expression is present very early during the development of the
disease andmay have a causal role in the onset of DM2. Consis-
tent with the downregulation of OXPHOSgene expression, other
studies have reported an impairment of mitochondrial oxidative
phosphorylation function in skeletal muscle of diabetic and
prediabetic subjects (Kelley et al., 2002; Petersen et al., 2003,
2004; Ritov et al., 2005). For instance, young, lean, insulin-
resistant offspring of parents with DM2 were found to have
a 30% reduction in rates of mitochondrial ATP synthesis in
skeletal muscle assessed by 31P NMR, which was associated
with increases in intramyocellular lipid content (Petersen et al.,
2004). Furthermore, healthy, lean, elderly subjects were found
to have severe skeletal muscle insulin resistance, which was
associated with increased intramyocellular and hepatic triglyc-
eride content and reduced rates of mitochondrial oxidativeC. DOI 10.1016/j.cmet.2006.11.003 453
A R T I C L Ephosphorylation activity compared to younger activity- and
body-weight-matched volunteers (Petersen et al., 2003). Finally,
recent studies in muscle biopsy samples obtained from patients
with DM2 have found a direct correlation between electron
transport chain activity and mitochondrial area and the rate of
insulin-stimulated glucose disposal (Kelley et al., 2002; Ritov
et al., 2005). While all of these studies have implicated mito-
chondrial dysfunction in the pathogenesis of insulin resistance
in humans, it remains to be determined whether mitochondrial
dysfunction precedes or follows the development of insulin
resistance.
Of note, peroxisome proliferator activator receptor g coacti-
vator 1a (PGC-1a) and 1b (PGC-1b) were also significantly less
expressed in insulin-resistant skeletal muscle (Mootha et al.,
2003; Patti et al., 2003). In contrast, Morino et al. (2005)
have recently shown that PGC-1a and PGC-1b expression in
skeletal muscle of young, lean, insulin-resistant offspring of
parents with DM2 is not altered. PGC-1a is a transcriptional
coactivator that has been shown to modulate the expression
of many genes in different biological programs (Puigserver
and Spiegelman, 2003) including mitochondrial oxidative me-
tabolism in vitro and in vivo. It promotes mitochondrial biogen-
esis and cellular respiration in several cell types, and also does
so when expressed transgenically in mice (Lehman et al.,
2000; St-Pierre et al., 2003; Wu et al., 1999). Moreover, DNA
microarray analysis following adenovirally mediated PGC-1a
expression in C2C12 muscle cells has shown increased ex-
pression of a subset of OXPHOS genes that greatly overlap
with those downregulated in skeletal muscle of diabetic/predi-
abetic humans (Mootha et al., 2004). Consistent with this,
a large number of OXPHOS genes were shown to be reduced
by 20%–50% in skeletal muscle of Pgc-1a null mice (Arany
et al., 2005).
PGC-1b was recently identified as the closest homolog to
PGC-1a (Lin et al., 2002a). PGC-1b has a wide tissue distribu-
tion, but it is most highly expressed in tissues of high oxidative
metabolism such as brown adipose tissue (BAT), heart, and
skeletal muscle (Lin et al., 2002a). It coactivates a broad range
of nuclear receptors and transcription factors (Kressler et al.,
2002; Lin et al., 2002a; Meirhaeghe et al., 2003) that partially
overlap with PGC-1a’s target transcription factors. There are
also transcription factors that are exclusively coactivated by
PGC-1b but not PGC-1a, such as the SREBP family (Lin
et al., 2005). PGC-1b has been far less studied than PGC-
1a; nevertheless, there is evidence that PGC-1b also regulates
mitochondrial metabolism. Adenovirally mediated PGC-1b ex-
pression in muscle cells, primary rat hepatocytes, and rat liver
induces the expression of genes of mitochondrial oxidative
metabolism, such as cytochrome c and b-ATPase (Lin et al.,
2003; St-Pierre et al., 2003). In addition, PGC-1b strongly
promotes mitochondrial proliferation and cell respiration in
muscle cells, (St-Pierre et al., 2003). These results strongly
suggest that PGC-1b is a major regulator of mitochondrial
metabolism.
In the present study, we have generated mice lacking exons
3 to 4 of the Pgc-1b gene (Pgc-1bE3,42/E3,42 mice) and used
these animals to investigate the function of PGC-1b in mito-
chondrial gene expression and function in liver and skeletal
muscle. We have also directly addressed the question of
whether a mutation in Pgc-1b causes insulin resistance in
mice.454Results
Generation of PGC-1b mutant mice
Mice homozygous for the Pgc-1b allele lacking sequences from
exon 3 to exon 4 (Pgc-1bE3,42/E3,42) (Figure 1A) were generated.
Our strategy was originally designed in an attempt to generate
Pgc-1b null mice. The sequence from exons 3 to 4, containing
two out of the three LXXLL motifs present in mouse PGC-1b,
was replaced by a neomycin cassette such that the splicing ac-
ceptor sequences of exon 3were retained and the splicing donor
sequencesof intron 4were deleted.Our expectationwas that the
neomycin cassette would be retained in the mature mRNA and
thusdisrupt the reading frameofPGC-1b.However, this cassette
was spliced out of the mature mRNA, and a mutant transcript
lacking the sequence from exon 3 to exon 4was generated. Het-
erozygousmice (Pgc-1b+/E3,42) weremated, andwild-type (WT),
heterozygous, and homozygous offspring (Figure 1B) were ob-
tained at the ratio consistent with Mendelian transmission
(1:2:1), thus indicating that deletion of exons 3 to 4 of Pgc-1b
does not cause lethality. The absence of transcripts containing
exons 3 and 4 was verified by northern blot analyses. Total
RNA samples from BAT and heart were analyzed with a probe
spanning exons 3 to 4. Both PGC-1b transcripts (w9 and 4 kb)
were detected in Pgc-1b+/+ RNA samples but were absent in
Pgc-1bE3,42/E3,42 RNA samples (Figure 1C), indicating the ab-
sence of mRNA containing exons 3 and 4 in Pgc-1bE3,42/E3,42
mice. In addition, total RNA of BAT was analyzed with a probe
spanning exon 5 of Pgc-1b, which is outside of the deleted re-
gion. Again, two Pgc-1b transcripts were observed in the Pgc-
1b+/+ BAT RNA sample. However, two Pgc-1b transcripts were
also observed in the Pgc-1bE3,42/E3,42 BAT RNA sample. These
were approximately 0.3 kb smaller than the former (Figure 1D).
The combined length of exons 3 and 4 is 330 nucleotides, and
a splicing event from exon 2 to exon 5 in Pgc-1b heterogeneous
nuclear RNA was a possible explanation for the occurrence of
such transcripts in Pgc-1bE3,42/E3,42 mice. This possibility was
tested by RT-PCR analysis of BAT, liver, and muscle total RNA
using primers spanning exons 2 to 5. Amplicons ofw1.1 kb and
w0.8 kbwere observed inPgc-1b+/+ andPgc-1bE3,42/E3,42 sam-
ples, respectively (Figure 1E). The splicing event from Pgc-1b
exon 2 to exon 5 in Pgc-1bE3,42/E3,42micewas confirmed by se-
quencingof the latter (0.8kb) amplicon. Thenucleotidesequence
of transcripts lackingexons3 and4 is in framewithPgc-1b’s start
codon, and the predicted amino acid sequence would lack 110
amino acids (from aa 85 to aa 194). The presence of this protein
was confirmed in BAT lysates by western blot analyses using
antisera raised against the N-terminal region of PGC-1b (aa 1
to aa 350) (Figure 1F). Of note, the amount of PGC-1b mutant
(MT) protein detected was substantially reduced. However, this
must be due to decreased antigen reactivity resulting from the
lack of protein encoded by exons 3 and 4 since we have demon-
strated that the PGC-1b antiserum detects the MT protein at an
efficiencyofw25%–50%compared to theWTprotein (Figure1F;
see also Figure S4 in the Supplemental Data available with this
article online). Thus, expression of the mutant protein is approx-
imately equal to expression of the WT protein.
Reduced coactivation of a subset of nuclear receptors
by PGC-1b mutant protein
The LXXLL sequence is a very important ligand-dependent nu-
clear hormone receptor-interacting motif of nuclear receptorsCELL METABOLISM : DECEMBER 2006
PGC-1b mutation causes hepatic insulin resistanceFigure 1. Generation of Pgc-1bE3,42/E3,42 mice
A) Schematic representation of the wild-type Pgc-1b
allele, the targeting construct, and the mutant Pgc-
1b allele after homologous recombination. Exons
are represented by filled boxes. EcoRI restriction
sites and the probe (represented by an open box)
used for Southern blot for genotyping of ES clones
are shown. The deletion of exons 3 to 4 includes
two out of the three canonical LXXLL motifs present
in the wild-type Pgc-1b gene.
B) Genotyping by PCR analysis of tail genomic DNA
of offspring of heterozygous (HET) crosses. The 150
bp and 300 bp amplicons for the wild-type (WT)
and mutant (MT) Pgc-1b alleles, respectively, are
indicated.
C)Northern blot analysis of brown fat (BAT) and heart
total RNA. A probe spanning Pgc-1b exons 3 and 4
was used. Pgc-1b mRNA signal was detected as
two bands at w9 and w4 kb in Pgc-1b+/+ BAT and
heart samples.
D) Northern blot analysis of BAT total RNA. A probe
spanning Pgc-1b exon 5 was used. Pgc-1b mRNA
was detected as two bands at w9 and w4 kb in
the Pgc-1b+/+ BAT mRNA sample. The MT Pgc-1b
mRNA was detected as two bands at w8.7 and
w3.7 kb in the Pgc-1bE3,42/E3,42BATmRNA sample.
E)RT-PCRanalysis of BAT, liver, and skeletal muscle
total RNA using primers located in Pgc-1b exons
2 and 5. The amplicons were 650 bp and 350 bp
for WT (left lanes) and MT (right lanes) mRNAs,
respectively.
F) Western blot analysis using rabbit polyclonal anti-
sera against the N terminus (aa 1–350) of the mouse
PGC-1b as the primary antibody. (Left panel) The
specific signal for PGC-1b was detected at w160
kDa in Pgc-1b+/+ BAT lysate. The PGC-1bMT signal
was detected atw150 kDa in Pgc-1bE3,42/E3,42 BAT
lysate. (Right panel) In vitro-translated WT or MT
PGC-1b proteins were used as controls. To control
for equal loading, rabbit polyclonal antisera against
YY1 (left panel) and mouse monoclonal anti-FLAG
antibody (right panel) were used. Note the reduced
affinity of the antisera against PGC-1b MT.(see, e.g., Savkur and Burris, 2004). The human PGC-1b con-
tains two LXXLL motifs, and the LXXLL motif encoded by exon
4 has been shown to be crucial for interaction with ERa (Kressler
et al., 2002). Thus, it seemed likely that the amino acids encoded
by exons 3 and 4 of PGC-1b, which includes two of three LXXLL
motifs present inmouse PGC-1b, would be required for its coac-
tivation activity toward some nuclear receptors. To test this, we
transiently cotransfected H2.35 hepatoma cells with plasmids
encoding nuclear receptors or other transcription factors and
equal amounts of plasmids encoding the PGC-1b WT or PGC-
1b MT protein. ERRa has been shown to be a critical factor in
the earliest stages of mitochondrial biogenesis induced by
PGC-1b (Mootha, et al., 2004; Schreiber et al., 2004). As shown
in Figure 2A, ERRa transactivates its own promoter, and PGC-
1b increases its transcriptional activity by w14-fold; PGC-1b
MT is substantially reduced in this activity, increasing reporter
gene expression by onlyw3-fold. NRF1 is also a crucial factor
in mitochondrial gene expression induced by the PGC-1s (Moo-
tha, et al., 2004). NRF1 binds to NRF1 recognition sites, and
PGC-1b WT activates its transcriptional activity by nearly 3-
fold. In contrast, activation by PGC-1b MT is negligible. Simi-CELL METABOLISM : DECEMBER 2006larly, HCF fused to a Gal4 DNA-binding domain binds to Gal4
DNA-binding motifs (UAS), and PGC-1b WT increases its tran-
scriptional activity byw20-fold, whereas PGC-1bMT increases
it by only w5-fold (Figures 2B and 2C). These results suggest
that amino acids encoded by exons 3 and 4 are required for
full coactivation of the transcription factors ERRa, NRF1, and
HCF. In sharp contrast, themutant protein has nearly normal ac-
tivity on several other transcription factors. SREBP1c fused to
a Gal4 DNA-binding domain binds to a Gal4 luciferase reporter
plasmid, and the WT increases its transcriptional activity by
more than 3-fold (Figure 2D). PGC-1bMT increases its transac-
tivation activity more than 2-fold. Similar results were also ob-
tained using SREBP1c on a fatty-acid synthase promoter lucif-
erase reporter plasmid (Figure S1A). Coactivation of LXRa and
PPARg by PGC-1b WT or PGC-1b MT was also tested (data
not shown) in the absence and presence of their respective li-
gands, T0901317 and rosiglitazone. PGC-1b WT and PGC-1b
MT were found to similarly activate those nuclear receptors in
the absence and presence of their ligands. These results sug-
gest that coactivation of SREBP1c, LXRa, and PPARg is not
greatly affected by deletion of amino acids encoded by exons455
A R T I C L E3 and 4. Taken together, these data suggest that amino acids 85
to 194 of PGC-1b are required for coactivation of ERRa, NRF1,
and HCF, but likely not for coactivation of SREBP1c, LXRa, and
PPARg.
Reduced expression of OXPHOS genes in liver
and skeletal muscle of PGC-1b mutant mice
To investigate whether this mutation in Pgc-1b results in alter-
ations in gene expression and several physiological functions,
we first performed transcriptional microarray analysis on RNA
samples obtained from liver and skeletal muscle. In liver, clus-
tering analysis of the microarray data revealed that expression
of many genes of mitochondrial metabolismwas downregulated
by 30%–40% in Pgc-1bE3,42/E3,42mice compared to Pgc-1b+/+
mice (Figure 3A). These genes include Ndufv1, Ndufs1, and
Ndufs7 (complex I subunits); Uqcrc1 (complex III subunit);
Coq7 (ubiquinone synthesis); Aco2 and Dlst (Krebs cycle); and
Sod2 (superoxide removal). G6pc and Cyp7a expression was
also found to be reduced. To validate the reduced expression
of these genes, we performed northern blot analysis (Figure 3B).
Consistent with the microarray data, the northern blots con-
Figure 2. Reduced coactivation of a subset of nuclear receptors/transcription
factors by PGC-1b mutant protein.
Mouse H2.35 hepatoma cells were transiently cotransfected with (A) ERRa-pro-
moter luciferase reporter and ERRa plasmids, (B) 43 NRF1-luciferase reporter
and NRF1 plasmids, (C) UAS-luciferase reporter and Gal-DBD-HCF plasmids, or
(D) UAS-luciferase reporter and Gal-DBD-SREBP1c plasmids along with
pCATCH-PGC-1b or pCATCH-PGC-1b mutant (MT) plasmids. pCMV-bGal was
added for transfection efficiency normalization. Cells were harvested 48 hr after
cotransfection and assayed for luciferase and b-galactosidase. The results repre-
sent the mean 6 SEM of at least three independent experiments.456firmed a reduction in the expression of these genes. Importantly,
all of the genes previously described as targets of PGC-1b-
SREBP1c interaction (Fasn, Scd1, and Hmgcr) (Lin et al.,
2005) were equally expressed in the livers of Pgc-1b+/+ and
Pgc-1bE3,42/E3,42 mice. The LXRa target genes (Pltp, Abca1,
Abcg1, Abcg8, and Add1) were similarly expressed in the two
groups, with the exception of Cyp7a, which was markedly re-
duced in liver of Pgc-1bE3,42/E3,42 mice. Quantitative PCR
(qPCR) demonstrated that Coq7 and Ndufs1 mRNA levels
were normal in heterozygous mice, suggesting no dominant-
negative or gain-of-function effect of the mutant allele. Ndufv1
mRNA levels were intermediate betweenwild-type and homozy-
gous mice, which is consistent with a gene-dosage effect (Fig-
ure S1B). Finally, expression of Pgc-1a mRNA (as assessed
by qPCR) was not altered in Pgc-1bE3,42/E3,42 mice, indicating
that PGC-1a did not compensate for decreased PGC-1b func-
tion in liver (data not shown).
Clustering analysis of the microarray data from quadriceps
muscle revealed that expression of several genes of mitochon-
drial oxidative metabolism was reduced in Pgc-1bE3,42/E3,42
RNA samples. These genes were reduced by 20%–30%, and
most of them were OXPHOS genes encoding subunits of com-
plexes I to V. Of note, Ndufv1, Ndufa8, Ndufs1, and Ndufb10
(complex I subunits); Sdhb and Sdhd (complex II subunits);
Uqcr, Uqcrc1, and Uqcrc2 (complex III subunits); Cox7a2 (com-
plex IV subunit); ATP5o and ATP5d (complex V); and cyto-
chrome c were all reduced in quadriceps muscle of Pgc-
1bE3,42/E3,42 mice (Figure 3C). qPCR assays were performed
for selected OXPHOS genes to confirm the expression pattern
shown by the microarray data. These studies revealed mRNA
content to be reduced by w30%–50% in quadriceps muscle
of Pgc-1bE3,42/E3,42 mice (Figure 3D). Quadriceps muscle is
composed mostly of type II fibers (white, glycolytic), and we
asked whether a similar reduction in those OXPHOS genes
would be present in a muscle such as gastrocnemius, which
contains both type I (red, oxidative) and type II fibers. The
qPCR assays revealed a marked reduction (30%–60%) in
mRNA content of OXPHOS genes in gastrocnemius of
Pgc-1bE3,42/E3,42 mice (Figure 3E). Also, we performed qPCR
assays in gastrocnemius samples for genes encoding proteins
characteristic of type I fibers, such as troponin I (slow) and myo-
globin, which are under PGC-1a’s regulation (Lin et al., 2002b).
No differences in the expression of these genes were observed
comparing samples of Pgc-1bE3,42/E3,42 and Pgc-1b+/+ mice
(data not shown). Taken together, these results demonstrate
conclusively that the amino acids encoded by exons 3 and 4
of PGC-1b are required for normal expression of many genes
of mitochondrial oxidative metabolism in liver and skeletal
muscle.
Reduced mitochondrial area and function in liver
and skeletal muscle of PGC-1b mutant mice
PGC-1b has been shown to strongly stimulate mitochondrial
biogenesis and cellular respiration in hepatocytes and muscle
cells, suggesting that PGC-1b is a critical regulator of mitochon-
drial proliferation and function. To test this genetically, we first
performed morphometric analysis of liver and skeletal muscle
(extensor digitorum longus [EDL] and soleus) by quantitative
electron microscopy. Liver and both types of skeletal muscle,
EDL (white, glycolitic) and soleus (red, oxidative), of Pgc-
1bE3,42/E3,42 mice contained a number of mitochondria similarCELL METABOLISM : DECEMBER 2006
PGC-1b mutation causes hepatic insulin resistanceFigure 3. Reduced expression of OXPHOS genes in liver and skeletal muscle of Pgc-1bE3,42/E3,42 mice
A) Clustering analysis of liver microarray data of Pgc-1b+/+ (WT) and Pgc-1bE3,42/E3,42 (MT) mRNA samples. Genes that were reduced in MT samples are indicated.
B) Northern blot analysis of WT andMT liver total RNA samples for validation of the microarray data. A probe specific for ribosomal protein 36B4 was included as a loading
control.
C) Clustering analysis of quadriceps skeletal muscle microarray data from WT and MT mRNA samples. Genes reduced in MT samples are indicated.
D) TaqMan quantitative real-time PCR (qPCR) analysis of WT and MT quadriceps total RNA samples for validation of the microarray data. The mRNA content of specific
genes was normalized to cyclophylin mRNA content. The mRNA levels are expressed relative to theWT values. Black bars represent WT; white bars represent MT. Results
are expressed as mean 6 SEM (n = 8–11). *p < 0.05; ***p < 0.001.
E) Expression of the same genes as in (D) was assessed by qPCR analysis of WT and MT gastrocnemius total RNA.to that observed in samples derived from Pgc-1b+/+ mice
(Figures 4A–4C). However, mitochondrial area in liver, EDL,
and soleus was greatly reduced in Pgc-1bE3,42/E3,42 samples
compared to Pgc-1b+/+ samples (Figures 4D–4F).
We next assessed mitochondrial function as measured by O2
consumption of isolated hepatocytes. A significant reduction of
basal O2 consumption (15%) was observed (Figure 4G). We alsoCELL METABOLISM : DECEMBER 2006assessed complex IV (COX) activity, which is a critical compo-
nent of the electron transport chain, in gastrocnemius muscle
homogenates. COX activity of Pgc-1bE3,42/E3,42 muscle ho-
mogenate was markedly reduced compared to that of Pgc-
1b+/+ mice (Figure 4H). These results show that PGC-1b is re-
quired to maintain normal mitochondrial function in liver and
skeletal muscle.457
A R T I C L EFigure 4. Reduced mitochondrial area and function
in liver and skeletal muscle of Pgc-1bE3,42/E3,42mice
A–C) Mitochondria number on electron micrographs
of liver (A), extensor digitorum longus (EDL; B), and
soleus skeletal muscles (C) from Pgc-1b+/+ and
Pgc-1bE3,42/E3,42 mice. Bars represent samples de-
rived from Pgc-1b+/+ (black) and Pgc-1bE3,42/E3,42
mice (white). Results are expressed as mean 6
SEM (n = 3–8). *p < 0.05; **p < 0.01; ***p < 0.001.
D–F) Average mitochondrial area was obtained by
computer-assisted morphometry on electron micro-
graphs of liver (D), EDL (E), and soleus skeletal mus-
cles (F) from Pgc-1b+/+ and Pgc-1bE3,42/E3,42 mice.
G) Basal O2 consumption was measured in hepato-
cytes of Pgc-1b+/+ and Pgc-1bE3,42/E3,42 mice.
H) Cytochrome c activity of gastrocnemius skeletal
muscle samples of Pgc-1b+/+ and Pgc-1bE3,42/E3,42
mice.Increased hepatic triglyceride content in the liver
of PGC-1b mutant mice
Despite clear data indicating that this is an early correlate of
insulin resistance in humans, it is unclear whether reduced
expression of the PGC-1 coactivators and OXPHOS genes is
a causal factor in insulin resistance. Thus, we investigated
several parameters involved in insulin/glucose homeostasis in
Pgc-1bE3,42/E3,42 mice. As shown in Table 1, both genotypes
had similar blood glucose and fatty-acid serum levels in both
the fed and fasted states. Serum triglycerides levels tended to
be lower in fed Pgc-1bE3,42/E3,42 mice but similar in both geno-
types in fasted mice (Table 1). Cholesterol and insulin serum
levels were normal in fed Pgc-1bE3,42/E3,42 mice. However,
a trend toward elevated insulin serum levels was observed in
fasted Pgc-1bE3,42/E3,42 mice (Table 1). Body weight was not
different between PGC-1b WT and MT mice (data not shown).
Serum adiponectin levels, total body fat content, and subscap-
ular brown fat-pad weights were normal in Pgc-1bE3,42/E3,42
mice (Table 1). Impairment of mitochondrial oxidative metabo-
lism may cause lipid accumulation, which has been strongly
associated with insulin resistance in liver and skeletal muscle
(Shulman, 2000). Thus, wemeasured triglyceride content in liver
and skeletal muscle. Triglycerides were significantly increased
in Pgc-1bE3,42/E3,42 livers compared to Pgc-1b+/+ livers, but
not in quadriceps, gastrocnemius, or soleus muscles (Table 1).458Of note, liver triglyceride levels were normal in heterozygous
mice (Figure S1C).
Hepatic insulin resistance in PGC-1b mutant mice
To further investigate insulin sensitivity and whole-body glucose
homeostasis, euglycemic-hyperinsulinemic clamp studies were
performed (Figures 5A–5D). Glucose infusion rate during the
clamps was similar in Pgc-1bE3,42/E3,42 mice and Pgc-1b+/+
mice (Figures 5A and 5B). Whole-body glycolysis and glycogen
synthesis were also similar in both genotypes (Figure 5C). Skel-
etal muscle glucose uptake was also similar (Figure 5C), indi-
cating the absence of skeletal muscle insulin resistance in
Pgc-1bE3,42/E3,42 mice. However, while insulin significantly
reduced hepatic glucose production rates in Pgc-1b+/+ mice
during the euglycemic-hyperinsulinemic clamp, it had no effect
on hepatic glucose production rates in Pgc-1bE3,42/E3,42 mice
(Figure 5D). These results indicate the presence of striking
insulin resistance in the liver of the PGC-1b mutant mice.
To further explore the mechanism for this, we measured the
ability of insulin to activate the PI3K-Akt pathway in liver and
muscle of the PGC-1b mutant mice. Specifically, we assessed
IRS-associated PI3-kinase activity and AKT activity in liver and
muscle in response to the hyperinsulinemic conditions of the
clamp (Figures 5E and 5F). Insulin-stimulated IRS-1-associated
PI3-kinase activity and Akt activity were similar in WT andCELL METABOLISM : DECEMBER 2006
PGC-1b mutation causes hepatic insulin resistancemutant gastrocnemius samples. In liver of Pgc-1bE3,42/E3,42
mice, insulin-stimulated IRS-2-associated PI3-kinase activity
tended to be reduced, and Akt activity was significantly reduced
compared to WT samples. These results demonstrate reduction
of biochemical actions of insulin in liver of Pgc-1bE3,42/E3,42
mice, but no alterations in skeletal muscle. Together, these
results suggest that insulin resistance in the liver of Pgc-
1bE3,42/E3,42 mice is explained, at least in part, by decreased
insulin-stimulated PI3K-Akt activation.
Finally, to assess whether this liver insulin resistance would
cause whole-body glucose intolerance and/or insulin resis-
tance, intraperitoneal insulin tolerance tests (ITTs) and glucose
tolerance tests (GTTs) were performed on mice of both
genotypes. At both 4 and 9 months of age, Pgc-1b+/+ and
Pgc-1bE3,42/E3,42 mice had similar blood glucose concentra-
tions during GTTs (data not shown). Also, according to the
ITTs in 4- and 9-month-old mice, a similar suppression of
blood glucose levels was observed in both Pgc-1b+/+ and
Pgc-1bE3,42/E3,42 mice (Figures 6A and 6B). These results indi-
cate that although Pgc-1bE3,42/E3,42mice have quite significant
hepatic insulin resistance, there is sufficient compensation by
other tissues and/or physiological systems to prevent whole-
body glucose intolerance and/or insulin resistance. Finally, to
see whether Pgc-1bE3,42/E3,42 mice have altered sensitivity to
high-fat-diet-induced insulin resistance, we fed mice a high-fat
diet for 12 weeks. Glucose levels in the fed state were equal in
wild-type and Pgc-1bE3,42/E3,42mice (data not shown). Also, in-
sulin tolerance tests were similar in high-fat-fed wild-type versus
Pgc-1bE3,42/E3,42 mice (Figure S2A).
Table 1. Body and blood composition of Pgc-1b+/+ (WT) and Pgc-1bE3,42/E3,42
(MT) male mice
WT MT
Glucose (mg/dl)
Fed 129 6 7 (10) 127 6 6 (11)
Fasted 63 6 3 (13) 66 6 2 (13)
Insulin (ng/ml)
Fed 1.41 6 0.13 (14) 1.62 6 0.13 (15)
Fasted 0.28 6 0.07 (13) 0.36 6 0.05 (16)
Adiponectin (mg/ml)
Fed 8.69 6 0.99 (6) 8.98 6 1.04 (6)
Fatty acids (mM)
Fed 0.67 6 0.05 (11) 0.77 6 0.07 (10)
Fasted 1.38 6 0.09 (14) 1.28 6 0.09 (13)
Triglycerides (mg/dl)
Fed 90.3 6 12.7 (9) 64.8 6 8.0 (9)
Fasted 109.8 6 23.2 (6) 84.7 6 24.9 (6)
Cholesterol (mg/dl)
Fed 148.2 6 11.3 (5) 158.8 6 12.5 (5)
Liver triglycerides (mg/g tissue)
Fed 3.82 6 0.58 (13) 7.76 6 0.75 (14)*
Muscle triglycerides (mg/g tissue)
Quadriceps 6.61 6 2.54 (4) 2.39 6 1.21 (4)
Gastrocnemius 4.11 6 0.81 (10) 3.81 6 1.28 (8)
Soleus 10.07 6 2.31 (6) 11.86 6 2.45 (6)
White adipose tissue (WAT) mass
Tissue mass (g) 4.85 6 0.88 (5) 4.99 6 0.59 (5)
Ratio of WAT mass
to body mass (%/g)
20.58 6 2.35 (5) 21.76 6 2.94 (5)
Brown adipose tissue fat-pad weight (mg)
Subscapular 87.9 6 15.29 (8) 83.5 6 14.60 (6)
Parameters were assessed in mice at 9–12 weeks of age. All data represent
mean 6 SEM. The number of animals per group is shown in parentheses.
* p < 0.05.CELL METABOLISM : DECEMBER 2006Discussion
Several reports have suggested that reduced expression of
genes encoding mitochondrial enzymes of oxidative phosphor-
ylation (OXPHOS) in skeletal muscle could play a critical role in
causing insulin resistance. However, whether these alterations
precede and cause the development of insulin resistance is
presently unknown (Lowell and Shulman, 2005). In this report,
wewere able to address this question inmice. To study the func-
tion of the transcriptional coactivator PGC-1b, which has been
suggested to regulate the expression of genes of mitochondrial
oxidative metabolism, we have generated mice lacking exons 3
to 4 of the Pgc-1b gene (Pgc-1bE3,42/E3,42 mice). These mice
have reduced expression of several OXPHOS genes as well as
smaller and functionally impaired mitochondria in liver and skel-
etal muscle. The data presented here show conclusively an im-
portant role for PGC-1b as a regulator of mitochondrial biology
in vivo. Furthermore, the Pgc-1bE3,42/E3,42 mice were used as
a model to test whether a mutation in Pgc-1b and subsequent
mitochondrial dysfunction causes insulin resistance. Impor-
tantly, Pgc-1bE3,42/E3,42 mice are not hyperactive (Figure S2A)
and have body weight (data not shown) and fat mass (Table 1)
similar to Pgc-1b+/+ littermates, making it feasible to assess
whether a primary reduction of OXPHOS genes is sufficient to
cause insulin resistance in muscle or liver. Similar rates of skel-
etal muscle glucose uptake in response to insulin were observed
in both genotypes of mice, indicating similar degrees of skeletal
muscle insulin sensitivity in Pgc-1bE3,42/E3,42 and Pgc-1b+/+
mice. Furthermore, insulin signaling in skeletal muscle, as as-
sessed by Akt and IRS-1-associated PI3-kinase activity, was
similar in Pgc-1bE3,42/E3,42 andPgc-1b+/+mice. Finally, a similar
suppression of blood glucose levels was also observed in ITTs
of both Pgc-1b+/+ and Pgc-1bE3,42/E3,42 mice fed a high-fat
diet (Figure S2B). These results suggest that PGC-1b-mediated
reductions in expression of OXPHOS genes per se do not cause
insulin resistance in skeletal muscle.
It is possible, however, that downregulation of OXPHOS
genes leads to the development of skeletal muscle insulin resis-
tance, but only in the presence of other mitochondrial alterations
that are absent in Pgc-1bE3,42/E3,42 mice. Despite the fact that
skeletal muscle mitochondria were functionally abnormal, we
did not observe any associated increases in intracellular lipid
content, which would have been anticipated if mitochondrial
fatty-acid oxidation was also impaired. Intramyocellular triglyc-
eride accumulation—and more importantly, increases in intra-
cellular diacylglycerol content—has been shown to cause insu-
lin resistance in skeletal muscle, and it is likely that its presence
is required for the development of insulin resistance (Dresner
et al., 1999; Griffin et al., 1999; Yu et al., 2002). On the other
hand, it is also plausible that reduced expression of PGC-1a
or PGC-1b is causally implicated in skeletal muscle insulin resis-
tance, but independently of the expression of OXPHOS genes.
Indeed, PGC-1a has been shown to regulate the expression of
Glut4 in muscle cells (Michael et al., 2001) and has also been
shown to control the formation of type I fibers (Lin, et al.,
2002b), the most insulin-sensitive type of skeletal muscle fiber.
Further studies with specific deletion of PGC-1a and PGC-1b
in skeletal muscle are required to definitively address these
questions.
In contrast, thismutation inPgc-1b clearly causes dysfunction
in the liver, including the induction of insulin resistance. PGC-1b459
A R T I C L EFigure 5. Euglycemic-hyperinsulinemic clamp
study and intracellular insulin signaling in Pgc-
1bE3,42/E3,42 mice
Mice were injected with 2.5 mU/kg/min of insulin.
Bars and circles represent Pgc-1b+/+ (black) and
Pgc-1bE3,42/E3,42 (white) mice. Results are ex-
pressed as mean 6 SEM (n = 6–11). *p < 0.05.
A–D) Euglycemic-hyperinsulinemic clamp studies
were performed on chow-fed 18- to 20-week-old
Pgc-1b+/+ and Pgc-1bE3,42/E3,42 male mice.
A and B) Plasma glucose levels (A) and glucose infu-
sion rate during clamp study (B) are shown.
C and D) Whole-body glycolysis, glycogen synthe-
sis, and gastrocnemius glucose uptake (C) and he-
patic insulin sensitivity parameters (D) are shown.
E and F) IRS-1- or IRS-2-associated PI3-kinase ac-
tivity and Akt activity in gastrocnemius (E) and liver
(F) are shown.has been recently shown to regulate the expression of lipogenic
genes and genes involved in lipid secretion by liver via the coac-
tivation of SREBP1c and likely LXRa, respectively (Lin et al.,
2005).We show here that PGC-1b is also required in liver for nor-
mal expression of genes encoding mitochondrial proteins, in-
cluding OXPHOS genes. However, according to the liver tran-
scriptional profile data, PGC-1b-SREBP1c target genes were
not reduced in Pgc-1bE3,42/E3,42 mice. This may be explained
by the fact that PGC-1b MT coactivates SREBP1c normally
in vitro. Indeed, these data are consistent with the known
SREBP1c docking site, which is located between amino acids
350 and 530 of PGC-1b, downstream of the region deleted in
the mutant PGC-1b (aa 85 to aa 194) (Lin et al., 2005).460The Pgc-1bE3,42/E3,42mice also show reduced mitochondrial
substrate oxidation, as assessed by oxygen consumption of iso-
lated hepatocytes, as well as an accumulation of triglycerides in
the liver. Since this hypomorphic mutation causes a deficiency
in expression of mitochondrial genes and mitochondrial func-
tion, it seems very likely that this is largely a consequence of
the poor coactivation of ERRa and NFR-1 by the mutant PGC-
1b. However, loss of coactivation of other transcription factors
as a contributing factor to the phenotype of these mice also
seems likely.
To examine the possibility that the Pgc-1bE3,42/E3,42
mutant allele could be functioning as a dominant-negative
and/or gain-of-function mutant or, alternatively, as a simpleFigure 6. Insulin tolerance tests in aged Pgc-1b+/+
and Pgc-1bE3,42/E3,42 male mice
Intraperitoneal insulin tolerance tests (ITT) were
performed in 4-month-old (A) and 9-month-old (B)
Pgc-1b+/+ and Pgc-1bE3,42/E3,42 male mice. Follow-
ing 4 hr without food, mice were injected with insulin
at 1.5 U/kg of body weight. Results are expressed as
mean 6 SEM (n = 5–8).CELL METABOLISM : DECEMBER 2006
PGC-1b mutation causes hepatic insulin resistanceloss-of-function mutant, we studied heterozygous animals. If
the mutant functioned in a dominant-negative and/or gain-of-
function manner, heterozygotes would be predicted to have
abnormalities similar to those observed in homozygotes. We
assessed Coq7, Ndufv1, and Ndufs1 mRNA expression in liver
as well as triglyceride levels in liver, four parameters that were
markedly abnormal in homozygous mice. Of note, in heterozy-
gous mice, Coq7 and Ndufs1mRNA levels, as well as triglycer-
ide levels, were unchanged compared towild-typemice.Ndufv1
mRNA levels were intermediate betweenwild-type and homozy-
gous mice which is consistent with a gene-dosage effect. Over-
all, these findings strongly suggest that abnormalities observed
in Pgc-1bE3,42/E3,42 mice are due to loss of PGC-1b function
and are not due to dominant-negative and/or gain-of-function
effects.
An association between intrahepatic lipid accumulation and
insulin resistance was observed in several previous studies of
other animal models (Kim et al., 2000; Neschen et al., 2005;
Samuel et al., 2004). Of course, other explanations for the intra-
hepatic lipid accumulation include increased hepatic lipogene-
sis or reduced lipoprotein secretion. Consistent with the possi-
bility of reduced lipoprotein secretion, serum TG levels tended
to be reduced in Pgc-1bE3,42/E3,42 mice. Related to this, it was
recently shown that PGC-1b coactivates Foxa2 and induces
expression of microsomal transfer protein (MTP), facilitating
the secretion of VLDLs (Wolfrum and Stoffel, 2006). Given this,
it is possible that MTP expression could be decreased in Pgc-
1bE3,42/E3,42 mice and, as such, could contribute to hepatic
steatosis. This scenario, however, is unlikely since Mtp
mRNA expression was not altered in Pgc-1bE3,42/E3,42 mice
(Figure S1D).
In summary, these results demonstrate that PGC-1b is re-
quired for normal expression of OXPHOS genes and mitochon-
drial function in the liver and suggest that mitochondrial dys-
function may be a cause of hepatic insulin resistance. An
understanding of the full range of the physiological effects of
deletion of PGC-1b must await creation of mice carrying a null
mutation.
Experimental procedures
Generation of PGC-1b mutant mice
The targeting plasmid was constructed using a BAC clone containing geno-
mic DNA derived from the SV129 mouse strain. Replacement of the Pgc-1b
gene exons 3 to 4 by a neomycin cassette, as well as cloning of DNA in
pGEM-T Easy Vector (Promega) for transfection of ES cells, was performed
using homologous recombination in the EL250 bacteria strain as described
by Lee et al. (2001). ES cell electroporation, selection, and screening were
performed using standard techniques. Neomycin-resistant ES cell clones
were screened for 50 and 30 end recombination. Screening of 30 end recom-
bination was performed by Southern blot (Figure S3A). The DNA of ES cell
clones was digested with EcoRI and analyzed with a probe outside of the
construct. Screening for 50 end recombination was performed by PCR
(Figure S3B). The ES clones with recombination of both ends (50 and 30
end) were injected into blastulas. The chimeric founders were bred to wild-
type C57BL/6 mice, and heterozygous mice were bred to obtain mice homo-
zygous for the wild-type Pgc-1b allele (Pgc-1b+/+) and the mutant Pgc-1b
allele (Pgc-1bE3,42/E3,42).
Animal care
All the experiments were performed in accordance with Beth Israel Deacon-
ess Medical Center and Yale University Institutional Animal Care and Use
Committee (IACUC) guidelines. Mice were housed in groups of two to four
at 22C–24C in a 14 hr light/10 hr dark cycle and fed chow diet (Teklad F6CELL METABOLISM : DECEMBER 2006Rodent Diet 8664, Harlan Teklad) and water ad libitum. Mice were fed
a high-fat, high-sucrose diet (Research Diets, D-12331) for 12 weeks where
indicated. All studies were performed with male mice 9–12 weeks of age
unless otherwise specified.
Transient transfections
pCATCH-FLAG-Pgc-1b was cloned as previously described (Lin et al.,
2002a). To clone pCATCH-FLAG-Pgc-1b mutant, the region spanning exon
1 to exon 5 was first amplified by RT-PCR using BAT mRNA and the primers
50-CCTGGATCCGCGGGGAACGACTGCGGCGC-30 (sense) and 50-GCCTTT
GTTTCCGTTGGCAGAG-30 (antisense) (non-Pgc-1b-specific sequence is
underlined for the sense primer, which includes a BamHI site). The amplified
product was digested with BamHI and cloned into BamHI sites of pCATCH-
FLAG-Pgc-1b. pCATCH-FLAG-Pgc-1b mutant clone (MT) was verified by
DNA sequencing.
H2.35 hepatoma cells (ATCC) were maintained in DMEM containing 4.5 g/l
glucose and supplemented with 200 nM dexamethasone and 4% FBS. Tran-
sient transfections were performed using SuperFect Reagent (Promega) ac-
cording to the manufacturer’s instructions. Cells were transiently cotrans-
fected with the indicated luciferase reporter (100 ng) and transcriptional
factor/nuclear receptor (10–20 ng) plasmids and equal amounts of PGC-1b
WT or PGC-1b MT plasmids (250–800 ng). pCMV-bGal (50 ng) was also in-
cluded as a control for transfection efficiency normalization. pCATCH with-
out inserted Pgc-1b was added if necessary for transfection of equal
amounts of DNA. Cells were harvested after 48 hr of transfection for lucifer-
ase and b-galactosidase assays (Tropix Inc.).
Gene transcription profile
Total RNA was extracted from liver and skeletal muscle using the RNeasy Kit
(QIAGEN), according to the manufacturer’s instructions. Synthesis of cRNA,
hybridization, and scanning of the Affymetrix Murine 430 2.0 chip was per-
formed by the Dana-Farber Cancer InstituteMicroarray Core Facility. Themi-
croarray data were analyzed by clustering analysis using d-Chip software (Li
and Wong, 2001). Microarray data were validated by northern blot or qPCR.
For northern blots, 20 mg of total RNA per sample was separated on a form-
aldehyde gel, transferred to nylon membrane, and hybridized with gene-
specific probes. For qPCR, cDNA was synthesized using the SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen Corp.), and the ampli-
fications were performed using TaqMan gene expression assays (Applied
Biosystems). Mtp primer (forward: 50-ATGATCCTCTTGGCAGTGCTT-30;
reverse: 50-TGAGAGGCCAGTTGTGTGAC-30) and probe (50-TCTCTGCTTC
TTCTCCTCCTACTCTGCTTC-30) were synthesized by Biosearch Technolo-
gies, Inc.
Electromicrograph morphometry
Tissues were dissected and fixed in 4% paraformaldehyde in 0.1 M phos-
phate buffer (pH 7.4). Samples were subsequently dehydrated and embed-
ded in plastic (JB-4, Electron Microscopy Sciences). Thin sections were ob-
tained with an MTX ultramicrotome (RMC) and examined with a transmission
electron microscope (CM10, Philips). Ten sections per sample were ana-
lyzed. Mitochondrial number represents the average of a total number of
w500 mitochondria analyzed per genotype.
O2 consumption and complex IV activity
To isolate hepatocytes, mice were anesthetized, and liver was perfused for 3
and 4minwith prewarmed (42C) liver perfusion and liver digestionmedia (In-
vitrogen), respectively. After perfusion, liver was quickly removed, minced,
and put into DMEM supplemented with 20% FBS. The cell suspension was
gently put through a cell strainer (70 mM) and collected in a Falcon tube.
Themedia volumewas brought to 40ml, and the cells were pelleted. The pel-
lets were resuspended in 30 ml of media. Cells were washed in media three
times in total. At the end, the cells were resuspended in a small volume of
DMEM for O2 consumption assay. O2 consumption was corrected by dry
weight of cells. Complex IV activity was performed as previously described
(Rustin et al., 1994). Gastrocnemius muscle samples were homogenized in
PBS buffer (pH 7.0) (1:10 w/v) using a Teflon homogenizer. The homogenates
were centrifuged (800 3 g, 10 min) and the supernatants were diluted in
SETH buffer (250 mM sucrose, 2 mM EDTA, 10 mM Tris-HCl, 50 U/ml hepa-
rin) at pH 7.4 for determination of cytochrome c oxidase activity. Activity was
normalized by protein content.461
A R T I C L EBody composition analysis
Body composition was assessed by dual-energy X-ray absorptiometry (MEC
LunarCorp). BAT mass was assessed by harvesting and weighing subscap-
ular BAT fat pads.
Serum metabolites
Tail-vein blood was collected from fed or 24-hr-fasted 9- to 12-week-old
mice. Blood was assayed for glucose level using a OneTouch FastTake gluc-
ometer (LifeScan Inc.), and serum was collected after blood centrifugation.
Insulin levels were determined by Rat Insulin ELISA (Crystal Chem Inc.). Se-
rum adiponectin levels were measured by Mouse Adiponectin ELISA (Linco
Research). Serum fatty acids, triglycerides, and cholesterol were assayed
using NEFA C, L-Type TG H, and Cholesterol CII kits, respectively (Wako
Chemicals USA, Inc.).
Tissue triglycerides
To measure triglyceride content in liver and skeletal muscle, triglycerides
were extracted using chloroform/MeOH. Approximately 100 mg of liver,
quadriceps, and gastrocnemius muscle biopsies andw9 mg of soleus mus-
cle were homogenized for 1min in 500 ml of buffer containing 50mM Tris-HCl
(pH 7.5), 5 mM EDTA, 300 mM mannitol, and 1 mM PMSF. Samples were
kept on ice. Two hundred microliters of this mix was transferred into a new
tube, and 5 ml of KOH and 800 ml of chloroform/MeOH (2:1) were added. Sam-
ples were vortexed vigorously, left for 5 min at room temperature, and centri-
fuged at 10,000 3 g for 10 min. Five hundred microliters of the bottom layer
was taken andmixed to an equal volume of chloroform/MeOH/H2O (3:48:47).
Samples were vortexed vigorously and spun at 10,000 3 g for 10 min. One
hundred and eighty microliters of the bottom layer was transferred to
a new tube and dried completely overnight. Fifty microliters of butanol/[Tri-
ton-X114:MeOH (2:1)] (30:20) was added to the dried samples, and TG levels
were assayed using the L-Type TG H Kit (Wako Chemicals USA, Inc.).
Euglycemic-hyperinsulinemic clamp studies and insulin
tolerance tests
Euglycemic-hyperinsulinemic clamp studies were performed with Pgc-1b+/+
and Pgc-1bE3,42/E3,42 littermates of 18–20 weeks of age. Body fat and lean
body mass were assessed by 1H magnetic resonance spectroscopy (Bruker
BioSpin). Six days before the experiment, an indwelling catheter was im-
planted into the left jugular vein. After an overnight fast, [3-3H]glucose
(HPLC-purified; PerkinElmer) was infused at a rate of 0.05 mCi/min for 2 hr
to assess the basal glucose turnover. Following this period, euglycemic-hy-
perinsulinemic clamp study was conducted for 120 min with a primed and
continuous infusion of human insulin (105 pmol/kg primed, 15 pmol/kg/min
infusion) (Novo Nordisk), and 20% dextrose was infused at variable rates
to maintain plasma glucose at basal concentrations (w6.7 mM). To estimate
insulin-stimulated whole-body glucose fluxes, [3-3H]glucose was infused at
a rate of 0.1 mCi/min throughout the clamps, and 2-deoxy-D-[1-14C]glucose
(2-[14C]DG; PerkinElmer) was injected as a bolus 75min after the beginning of
the clamp studies to estimate the rate of insulin-stimulated tissue glucose up-
take. After the clamp studies, liver and gastrocnemius muscle were rapidly
removed and stored for later analysis of insulin signaling. Whole-body and
tissue glucose uptakes were calculated as previously described (Youn and
Buchanan, 1993). For insulin tolerance tests, mice were fasted for 4 hr before
receiving an intraperitoneal injection of insulin at 1.5 mU/g. Blood glucose
levels were collected from tail before and at 15, 30, 60, 90, and 120 min after
insulin infusion. Glucose levels were determined using a OneTouch FastTake
glucometer (LifeScan Inc.).
Immunoblotting
BAT was homogenized in lysis buffer (50 mM Tris [pH 7.8], 137 mM NaCl,
10 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.2% sarkosyl, 10% glycerol,
and protease inhibitor), solubilized by continuous stirring for 1 hr at 4C,
and clarified by centrifugation. In vitro-translated proteins were prepared
from 1 mg of wild-type and mutant pCATCH-FLAG-Pgc-1b plasmid DNA us-
ing the TnT T7 Coupled Reticulocyte Lysate System (Promega) according to
the manufacturer’s protocol. Tissue lysates and in vitro-translated proteins
were separated by SDS-PAGE and transferred onto a nitrocellulose mem-
brane by electroblotting. PGC-1b was detected using rabbit polyclonal
antisera against the N terminus (aa 1–350) of the mouse PGC-1b. The462in vitro-translated FLAG protein was detected using monoclonal ANTI-
FLAG M2 antibody (Sigma).
Determination of IRS-1- or IRS-2-associated PI3K and Akt activity
To prepare gastrocnemius and liver lysates, 50 mg of tissue was homoge-
nized using a polytron at half maximum speed for 1 min on ice in 500 ml buffer
(20 mM Tris [pH 7.5], 5 mM EDTA, 10 mM Na4P2O7, 100 mM NaF, 2 mM
Na3VO4) containing 1% NP-40, 1 mM PMSF, 10 mg/ml aprotinin, and
10 mg/ml leupeptin. Tissue lysates were solubilized by continuous stirring
for 1 hr at 4C and centrifuged for 10 min at 14,000 3 g. The supernatants
were stored at280C until analysis. Tissue lysates (500 mg protein) were sub-
jected to immunoprecipitation for 4 hr at 4C with 5 ml of either a polyclonal
IRS-1 antibody or a polyclonal IRS-2 antibody (1:100 dilution; gift from
Dr. Morris White, Joslin Diabetes Center) or 2 mg of Akt antibody that
recognizes both Akt1 and Akt2 (Upstate Biotechnology) coupled to protein
A-Sepharose (Sigma) or protein G-Sepharose beads. The immune complex
was washed, and PI3K and Akt activity were determined as described previ-
ously (Kim et al., 2002).
Statistical analysis
All results are expressed as means 6 SEM. Two-tailed Student’s t test was
used to determine p values.
Supplemental data
Supplemental Data include four figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/4/6/453/DC1/.
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